Spirovant is developing a gene therapy for cystic fibrosis (CF), the first curative treatment for this disease.  Talee has developed a novel transgene and a number of innovations in a well-characterized delivery vector that collectively will overcome challenges that have previously limited the clinical viability of gene therapy for CF. Talee Bio is a collaboration among drug development professionals with more than 60 years of combined experience, and academic founders of the company, from the University of Iowa, who have been investigating CF pathogenesis and treatment, including gene therapy strategies, for more than 25 years.

Immunome uses the human immune system to discover and develop novel targets and therapies to treat cancer. New cancer-specific targets are identified by obtaining B-cells from patients who have shown an immune response against their cancer.

Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.

Integrating broad collaborations with the University of Pennsylvania (UPenn) and the University of Minnesota with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders, Tmunity is developing personalized immunotherapies for cancer, infectious disease and autoimmune disease that are advancing rapidly toward the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of T cell therapies.



Eliksa Therapeutics is a regenerative medicine biotechnology company with proprietary technology, cGMP production facility and a robust clinical pipeline addressing unmet medical needs in ocular, cardiovascular and other difficult to treat indications. The lead product candidate, ELK-003, is a novel, multi-target biologic modulating inflammation, cell recovery, and tissue healing.

RiboNova is a biopharmaceutical company with a clinical-stage small molecule drug for the treatment of inherited mitochondrial disease, a devastating rare condition with no approved treatments. The company also has a proprietary drug discovery platform, which targets tRNA with novel precision medicines.